Author: Admin Roshan

Mitochondria and the Electron Transport Chain  Mitochondria are organelles within eukaryotic cells, and are responsible for generating energy. This energy is in the form of

On April 26, 2025, thousands gathered in New York City’s Central Park for the 31st annual Parkinson’s Unity Walk, a cornerstone event hosted by The

The right self-care practices can make patients and caregivers confident about making it through the journey when diagnosed with Parkinson’s disease. Self-care, from finding hobbies

Gain Therapeutics shared important updates at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases. The company presented new preclinical data as well as

April is Parkinson’s Awareness Month, a time to raise awareness about Parkinson’s disease (PD), support those living with it, and contribute to vital research for

The world’s leading experts in neurodegenerative diseases gather at the AD/PD Conference (Alzheimer’s Disease and Parkinson’s Disease) to present groundbreaking research, share insights, and discuss

What is the UPDRS? The Unified Parkinson’s Disease Rating Scale, or UPDRS, is an assessment tool designed to assist clinicians and researchers in evaluating the

How are human clinical trials conducted? Before human trials even begin, animal trials are conducted first to evaluate safety. Once human trials begin, they move

This September Gain Therapeutics is attending and presenting at two conferences. H.C. Wainwright 26th Annual Global Investment Conference The H.C. Wainwright 26th Annual Global Investment

Ryan Reynolds, the charismatic star of “Deadpool & Wolverine,” recently opened up about his father’s battle with Parkinson’s disease, shedding light on the early symptoms

Biomarkers and their use in therapeutic development Biomarkers are specific characteristics that can be used to predict the risk of disease, identify the presence of

Summary: At the Annual Neuro Perspectives Virtual Conference hosted June 27th, H.C. Wainwright hosted a Fireside Chat with Ram Selvaraju, a Senior Healthcare Equity Research

Parkinson’s disease (PD) remains a significant challenge in neurodegenerative research, with the GBA1 mutation presenting a particularly aggressive form of the disease. Gain Therapeutics is

Neurodegenerative diseases and the immune system Neurodegenerative diseases, such as Parkinson’s, Alzheimer’s, Huntington’s, and Motor Neuron diseases, are generally thought of in their capacity as

Read the research article in full. Mucopolysaccharidosis type I (MPS I) is a rare lysosomal storage disease (LSD) that arises from mutations in the gene

The new CFO fills in the missing link When you think of a Chief Financial Officer, the first thing that comes to mind is not

The links between Alzheimer’s, Parkinson’s, and Prion diseases At first glance, neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and prion disease share many generalized features. While

Part 3 Interview with Jonas Hannestad, MD, PhD – Chief Medical Officer In Part 3 of our discussion with Gain’s Chief Medical Officer Jonas Hannestad,

Part 2 Interview with Jonas Hannestad, MD, PhD – Chief Medical Officer In Part 2 of our discussion with Gain’s Chief Medical Officer Jonas Hannestad,

What this means for the future of Parkinson’s disease On May 23, 2024, Congress officially passed the National Plan to End Parkinson’s Act (H.R.2365/S.1064). The

Gain Therapeutics, Inc. reports promising results from its Phase 1 trial of GT-02287, a novel therapy for GBA1 Parkinson’s disease. The study indicates the therapy is safe and well-tolerated, enhancing GCase enzyme function, which is pivotal in combating the disease’s progression.

Meet Gain Therapeutics’ New Chief Medical Officer: Dr Jonas Hannestad, MD, PhD

This blog discusses Parkinson’s Disease, highlighting its history, characteristics, and ongoing research. Initiatives like the PD GENEration study offer free genetic testing. Gain Therapeutics is developing GT-02287, a potential disease-modifying drug for GBA1-Parkinson’s, with support from prominent foundations and currently conducting clinical trials.

Explore the innovative world of Gain Therapeutics in this engaging fireside chat held by Lou Basenese and Jeb Terry at the recent Public Ventures Discovery Day event. Delve into how we are revolutionizing the treatment of neurodegenerative diseases, including Parkinson’s, with our next-generation Magellanᵀᴹ platform. Gain harnesses AI and physics-based methods to develop best-in-class small molecules for disorders with high unmet medical needs. Hear about the significant strides we’ve made from current Board Member and former Gain CEO Eric Richman. A must-watch for those interested in the intersection of biotechnology, AI, and healthcare advancements.

Analyzing data from Genome Wide Association Studies (GWAS) and drawing from the insights of the PD GENEration Study, Dr. Alcalay unveils the significance of glucocerebrosidase (GBA) mutations in Parkinson’s. Discover why GBA emerges as a prime target for therapeutic interventions, offering hope for tailored treatments and improved patient outcomes.

Professor Outeiro provides an in-depth exploration of Parkinson’s disease from the perspective of a seasoned basic scientist. Covering topics ranging from disease complexity and classification to emerging biomarkers and therapeutic strategies, he delves into the intricacies of Parkinson’s research, highlighting the challenges faced by scientists and clinicians alike.

Joanne Taylor highlights the groundbreaking work of Gain Therapeutics in developing GT-02287, a GBA modulator, as a potential treatment for Parkinson’s disease. She discusses the origin of GT-02287, its mechanism of action, and preclinical findings demonstrating its efficacy in addressing key pathological features of Parkinson’s disease.